The synthesis of 4-thiazolidinone derivatives using 2-(4-R-2-formylphenoxy)-N-(R’-phenyl)acetamides and their anti-inflammatory activity

Authors

  • S. M. Golota Lviv National Medical University named after Danylo Halytsky, Ukraine
  • K.. E. Danylyuk National Pirogov Memorial Medical University, Ukraine
  • T. I. Yushchenko National Pirogov Memorial Medical University, Ukraine
  • N. I. Voloshchuk National Pirogov Memorial Medical University, Ukraine
  • O. V. Bilyk National Pirogov Memorial Medical University, Ukraine
  • R. B. Lesyk Lviv National Medical University named after Danylo Halytsky, Ukraine

DOI:

https://doi.org/10.24959/ophcj.15.852

Keywords:

4-thiazolidinones, NSAIDs, 2-(4-R-2-formylphenoxy)-N-(R’-phenyl)acetamides, anti-exudative activity

Abstract

The research is devoted to the rational design of new non-steroidal anti-inflammatory drugs (NSAIDs) using the 4-thiazolidinone “core”. A series of 2-(4-R-2-formylphenoxy)-N-(R’-phenyl)acetamides has been synthesized from salicylic aldehydes for structural modifications of basic heterocycles. The aldehydes obtained are active carbonyl agents and suitable “building blocks” for the focused synthesis of biologically active compounds. Ylidene derivatives of 2-thioxo-4-thiazolidinone and 2-(4-hydroxyphenyl)imino-4-thiazolidone have been synthesized in the Knoevenagel reaction conditions. The one-pot reaction between 3(5)-merkapto-1,2,4-triazoles, chloroacetic acid and the salicylic aldehyde derivatives synthesized have been used for the synthesis of 5-ylidene-thiazolo[3,2-b][1,2,4]triazol-6-one. Parameters of acute toxicity and the anti-exudative activity (carrageenin paw edema test) have been studied for the ylidene derivatives synthesized. It has been found that all compounds synthesized demonstrate the anti-exudative activity, and some “structure – acute toxicity – anti-exudative activity” relationships have been analyzed. Based on the results of in vivo studies the lead compound – 4-{2-[4-chloro-2-(6-oxothiazolo[3,2-b][1,2,4]triazole-5-ylidenemethyl)-phenoxy]- acetylamino}-benzoic acid ethyl ester that demonstrates the anti-exudative activity equivalent to the classic NSAID Diclofenac has been identified, it has a low level of toxicity and can be recommended for the profound study.

Downloads

Download data is not yet available.

References

  1. Green G. A. Clinical Cornerstone, 2001, Vol. 3, No.5, pp.50-59.
  2. http://compendium.com.ua/atc/M01#M01A_B05
  3. Laine L. J. Cardiovasc. Pharmacol., 2006, Vol. 47, No.1, pp.60-66.
  4. Graham D. J. JAMA, 2006, Vol. 296, No.13, pp.1653-1656.
  5. Gambaro G., Perazella M. A. J. Internal Medicine, 2003, Vol. 253, pp. 643-652.
  6. Brash A. R. J. Clin. Invest., 2001, Vol. 107, No.11, рp. 1339-1345.
  7. Levin J. I., Laufer S. Royal Society of Chemistry, 2012, 528 p.
  8. Dennis E. A. et al. Chem. Rev., 2011, Vol. 111, No.10, pp. 6130-6185.
  9. Praveen Rao P. N., Knaus E. E. J. Pharm. Pharmaceut. Sci., 2008, Vol. 11, No.2, pр. 81s-110s.
  10. Seno K. et al. J. Med. Chem., 2000, Vol. 43, No.6, pp. 1041-1044.
  11. Ottana R. et al. Bioorg. Med. Chem., 2005, Vol. 13, pp.4243-4252.
  12. Charlier C., Mishaux C. Eur. J. Med. Chem., 2003, Vol. 38, pp.645-659.
  13. Geronikaki А. A. et al. J. Med. Chem., 2008, Vol. 51, No.6, pp.1601-1609.
  14. Michalik L. et al. Pharm. Rev., 2006, Vol. 58, No.4, pp.726-741.
  15. Grygiel-Górniak B. Nutrition J., 2014, Vol. 13, pp.17.
  16. Lesyk R. et al. Boll. Chim. Farm., 1998, Vol. 137, No.6, pp.210-217.
  17. Zimenkovsky B. et al. Eur. J. of Pharm. Sci., 1998, Vol. 6., Suppl. 1, p.119.
  18. Lesyk R. et al. Eur. J. of Pharm. Sci., 1999, Vol. 8., Suppl. 2, p.27.
  19. Zimenkovsky B. et al. J. Pharm. Pharmacol., 1999, Vol. 51. p.264.
  20. Lesyk R. et al. Boll. Chim. Farm., 2002, Vol. 141, No.3, pp.197-201.
  21. Lesyk R. B. et al. Farmac. Zhurn. – Pharm. J., 2003, No.5, pp.58-61.
  22. Pastushenko T. V. et al. Hihiena i Sanitarija – Hygiene&Sanitary, 1985, No.6, pp.46-48.
  23. Sidorov K. K. Toksikologiya novykh promyshlennykh khimicheskikh veschestv (Toxicology of new industrial chemical substances), M.: Medicina, 1973, Vyp.3, p.47.
  24. Morris C. J. Inflammation Protocols. Methods in Molecular Biology, 2003, Vol. 225, pp.115-121.
  25. Stefanov O. V. Doklіnіchnі doslіdzhennya lіkarskyh zasobіv: Metodychnі rekomendatsіi (Preclinical studies of drugs. Guidelines), Kyiv, 2001, 528 p.

Downloads

Published

2015-09-10

How to Cite

(1)
Golota, S. M.; Danylyuk, K. E.; Yushchenko, T. I.; Voloshchuk, N. I.; Bilyk, O. V.; Lesyk, R. B. The Synthesis of 4-Thiazolidinone Derivatives Using 2-(4-R-2-Formylphenoxy)-N-(R’-phenyl)acetamides and Their Anti-Inflammatory Activity. J. Org. Pharm. Chem. 2015, 13, 15-20.

Issue

Vol. 13 No. 3(51) (2015)

Section

Original Researches

License

Copyright (c) 2015 National University of Pharmacy

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors publishing their works in the Journal of Organic and Pharmaceutical Chemistry agree with the following terms:

1. Authors retain copyright and grant the journal the right of the first publication of the work under Creative Commons Attribution License allowing everyone to distribute and re-use the published material if proper citation of the original publication is given.

2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal’s published version of the work (e.g., post it to an institutional repository or publish it in a book) providing proper citation of the original publication.

3. Authors are permitted and encouraged to post their work online (e.g. in institutional repositories or on authors’ personal websites) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (see The Effect of Open Access).